News & Events
September 15, 2022
Rare Disease Workshop Highlights the Importance of Data Sharing in Drug Development
RDCA-DAP® hosted an all-day workshop and annual meeting September 13 and 14 in Washington. The in-person and livestream event for rare disease stakeholders featured expert presentations, panel discussions, platform demonstrations, and was attended by more than 200 patients, researchers, clinicians, biopharmaceutical company representatives, regulatory reviewers and scientists.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path......
August 25, 2022
Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug DevelopmentC-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platform on rare disease drug development TUCSON, Ariz. and WASHINGTON, DC, August 25, 2022 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) will host its in-person annual workshop on September 13......
July 14, 2022
C-Path’s Dr. Amanda Klein Promoted to Transplant Therapeutic Consortium Executive DirectorTUCSON, Ariz., July 14, 2022 — Critical Path Institute (C-Path) has named Amanda Klein, Pharm.D., as Executive Director for its Transplant Therapeutics Consortium (TTC) effective immediately. Klein is a clinical pharmacist with a unique and extensive clinical practice and scientific background. Before joining C-Path, she served patients with complex chronic diseases (diabetes, cirrhosis, hepatitis C,......
June 16, 2020
C-Path’s Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint
TUCSON, Ariz., June 17, 2020 — Critical Path Institute (C-Path) announced today that its Transplant Therapeutics Consortium (TTC) has received a positive response to its Letter of Intent (LOI) from the U.S. Food and Drug Administration (FDA) detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program (BQP).